HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

TMC120-R147681

effectively prevented human immunodeficiency virus (HIV) infection in cocultures of monocyte-derived dendritic cells and T cells, representing primary targets in sexual transmission
Also Known As:
Dapivirine
Networked: 11 relevant articles (0 outcomes, 3 trials/studies)

Bio-Agent Context: Research Results

Experts

1. Nel, Annalene M: 2 articles (10/2010 - 07/2009)
2. Smythe, Shanique C: 2 articles (10/2010 - 07/2009)
3. Romano, Joseph W: 2 articles (10/2010 - 03/2008)
4. Baeten, Jared: 1 article (01/2015)
5. Naidoo, Sarita: 1 article (01/2015)
6. Husnik, Marla J: 1 article (01/2015)
7. Mgodi, Nyaradzo: 1 article (01/2015)
8. Pather, Arendevi: 1 article (01/2015)
9. Jeenarain, Nitesha: 1 article (01/2015)
10. Siva, Samantha: 1 article (01/2015)

Related Diseases

1. Infection
2. HIV Infections (HIV Infection)
10/01/2010 - "Dapivirine, a nonnucleoside reverse transcriptase inhibitor, is in development as a microbicide for the protection of women against HIV infection. "
01/01/2004 - "A 24-h treatment with 1,000 nM UC-781 or 100 nM TMC120-R147681 prevented cell-free HIV infection, whereas 10-fold-higher concentrations blocked cell-associated HIV."
11/01/2012 - "Recent studies suggest that the vaginal delivery of antiretroviral (ARV) agents - such as tenofovir, dapivirine and UC781 - may be a promising way to reduce the high rates of HIV infection among women in developing countries. "
01/01/2004 - "The nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 (Dapivirine) effectively prevented human immunodeficiency virus (HIV) infection in cocultures of monocyte-derived dendritic cells and T cells, representing primary targets in sexual transmission. "
09/01/2008 - "Foremost among the newly described antiviral agents that may be developed into drugs are, for the treatment of human papilloma virus (HPV) infections, cPrPMEDAP; for the treatment of herpes simplex virus (HSV) infections, BAY 57-1293; for the treatment of varicella-zoster virus (VZV) infections, FV-100 (prodrug of Cf 1743); for the treatment of cytomegalovirus (CMV) infections, maribavir; for the treatment of poxvirus infections, ST-246; for the treatment of hepatitis B virus (HBV) infections, tenofovir disoproxil fumarate (TDF) (which in the meantime has already been approved in the EU); for the treatment of various DNA virus infections, the hexadecyloxypropyl (HDP) and octadecyloxyethyl (ODE) prodrugs of cidofovir; for the treatment of orthomyxovirus infections (i.e., influenza), peramivir; for the treatment of hepacivirus infections (i.e., hepatitis C), the protease inhibitors telaprevir and boceprevir, the nucleoside RNA replicase inhibitors (NRRIs) PSI-6130 and R1479, and various non-nucleoside RNA replicase inhibitors (NNRRIs); for the treatment of human immunodeficiency virus (HIV) infections, integrase inhibitors (INIs) such as elvitegravir, nucleoside reverse transcriptase inhibitors (NRTIs) such as apricitabine, non-nucleoside reverse transcriptase inhibitors (NNRTIs) such as rilpivirine and dapivirine; and for the treatment of both HCV and HIV infections, cyclosporin A derivatives such as the non-immunosuppressive Debio-025."
3. Poxviridae Infections
4. Papilloma (Papillomatosis)
5. Orthomyxoviridae Infections

Related Drugs and Biologics

1. RNA-Directed DNA Polymerase (Reverse Transcriptase)
2. Rilpivirine (TMC-278)
3. UC 781
4. Nevirapine (Viramune)
5. Urea (Carbamide)
6. MIV 150
7. tenofovir
8. 2- phenyl- 6- (2'- (4'- (ethoxycarbonyl)thiazolyl))thiazolo(3,2- b)(1,2,4)triazole
9. Reverse Transcriptase Inhibitors
10. TMC120-R147681

Related Therapies and Procedures

1. Female Contraceptive Devices (Vaginal Ring)